For the year ending 2025-12-31, SER made $130K in revenue. -$19,182K in net income. Net profit margin of -14755.38%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenues | 130 | 56 | ||
| Research and development | 13,155 | 7,480 | ||
| General and administrative | 10,997 | 9,624 | ||
| Total operating expenses | 24,152 | 17,104 | ||
| Loss from operations | -24,022 | -17,048 | ||
| Other income, net | - | 228 | ||
| Interest expense | 213 | 526 | ||
| Change in fair value of convertible promissory notes | 0 | - | ||
| Change in fair value of warrants liabilities | -4,263 | -13,156 | ||
| Gain on warrants expiration | 724 | - | ||
| Change in fair value of convertible promissory notes | - | 7,017 | ||
| Other income, net | 51 | - | ||
| Total other income, net | 4,825 | 5,841 | ||
| Loss before income taxes | -19,197 | - | ||
| Provision for income taxes | 18 | - | ||
| Net loss | -19,215 | -11,207 | ||
| Net loss attributable to noncontrolling interest | -33 | -66 | ||
| Net loss attributable to serina | -19,182 | -11,141 | ||
| Basic EPS | -1.91 | -1.51 | ||
| Diluted EPS | -1.91 | -1.51 | ||
| Basic Average Shares | 10,190,000 | 7,359,000 | ||
| Diluted Average Shares | 10,190,000 | 7,359,000 | ||
Serina Therapeutics, Inc. (SER)
Serina Therapeutics, Inc. (SER)